The articles in this issue address the high prevalence and substantial clinical burden of multiple chronic conditions (MCC) among adults. All of these papers further the goals outlined in the US Department of Health and Human Services (DHHS) MCC Strategic Framework (
Each of these articles explores different data sources, and despite the variation in disease and condition combinations selected, these articles show the ability of many US federal datasets to address and better characterize the scope of MCC as well as incorporate important MCC-related issues such as the effect of MCC on the cost of clinical care and the extent of clinical care use. Collecting data from multiple sources, including population surveys and claims data, and from both institutional settings and ambulatory primary care allows triangulation and better comprehension of this issue. Although the challenges of the complex MCC patient have long been recognized, these articles highlight national prevalence rates and implications for prevention, diagnosis, management, and important outcomes. Here we suggest some directions for addressing MCC in the future and offer suggestions on how to address this complexity on the basis of the work presented in this issue and the growing body of emerging information on MCC.
A detailed exposition on defining a distinct disease or condition is beyond the scope of this discussion, but important considerations abound. Here we examine some MCC-relevant issues related to such definitions. In this issue, Goodman et al have contributed importantly to solving this problem (
Defining a chronic condition and MCC requires careful consideration. Many have defined such conditions on the basis of duration as conditions lasting at least 6 to 12 months; in the DHHS Framework (
Another issue is whether to consider many infectious diseases as chronic conditions. Goodman et al (
How do you deal with complex clinical manifestations of conditions, such as signs (visually observable patient abnormalities), symptoms (abnormal perceptions of illness that only the patients can report, such as pain, itching, fatigue, depressive feelings), and syndromes (clusters of signs, symptoms, and other clinical phenomena that may or may not be indicative of a specific underlying disease)? Do these belong in the study of MCC? Our answer is that these signs, symptoms, and syndromes must be carefully and systematically addressed, since many never reach the level of a specific diagnosable “disease” with an ICD code; however, they can cause considerable suffering and require health care .
An “individual” disease — is it one or many? Many diseases that are regarded as single entities exhibit diverse organ involvement and, over time, special and distinct clinical manifestations and sequellae. For example, diabetes mellitus is clearly associated with coronary heart disease, renal insufficiency, retinal disease, skin abnormalities, and other important clinical problems. Should each of these be considered separately in the multiplicity of MCC or as part of 1 condition for analytical purposes? Again, it depends on the question being addressed.
How should the “secondary outcomes” of a variety of biologically unrelated chronic conditions be considered and counted? Many chronic conditions clearly lead to a variety of unfortunately common and functional outcomes that are not necessarily related to the underlying causes or pathogenesis of the primary disease, including falls, cognitive impairment, anemia, malnutrition, polypharmacy, sleep disorders, and sexual dysfunction. Among older persons, some of these conditions have been called “geriatric syndromes” (
In counting diseases and conditions, at least 2 other issues remain. First, how should adverse effects of therapy be counted; they can be costly and deadly (
There are many issues that impinge on the quality of data used to assess MCC that relate to all population data on disease occurrence, as well as to their risk factors, prevention, treatment, and outcomes. Here are some of the central ones:
Maintaining a consensual, standard nomenclature and taxonomy is, of course, critical for quantifying diseases and conditions in community and health care settings, and equally critical for counting disease co-occurrences and permutations of MCC as well as understanding their outcomes (
New research on taxonomy and nomenclature will not only change the taxonomic systems currently in place; it will improve the understanding of disease causation and management. An important example of this is the ability to empirically cluster various individual diseases in terms of how “close” they are to each other with respect to their known pathogenic mechanisms (
Not all persons with diseases have full and equal access to medical care, and thus some diseases and conditions are never identified. Even where full care access is present, professional variation in disease screening, diagnosis, and treatment will occur among individual practitioners and across health care institutions and systems (
In the United States, there are no comprehensive, clinical record-based datasets for all ages and regions. Even the robust US Medicare databases do not currently have diagnostic data for people in managed care programs, and Medicare does not generally cover dental care (
What diseases and conditions should be included in the study of MCC? A remaining issue is that given the thousands of rubrics in the ICD, which are most important. The DHHS has selected 21 chronic conditions to begin emphasizing the problem (
Work on the application of MCC is proceeding rapidly. Alternative conceptualizations of MCC have been offered (
In the end, however, the value of collecting data on MCC, as with all scientific information, depends on how it will be used: whether it is understanding the natural history of diseases, applying clinical preventive interventions, identifying high-risk populations, making clinical or administrative decisions, counseling patients, or planning and evaluating large public health and prevention policies. It appears that much of what we know about health today derives from studying 1 disease at a time. Only recently has this begun to change. Public health has been a leader in addressing the clustering and effect of diverse conditions and MCC. For public health, the challenge will be to define preventive strategies that effectively deal with MCC, both before and after the doctor comes. Most challenging of all may be developing preventive strategies in the community that can favorably alter long-term clinical outcomes, and perhaps and hopefully alter the risk of acquiring multiple conditions after the first one has occurred.
This collection of articles demonstrates the richness of federal databases for understanding the occurrence and clustering of MCC; this commentary highlights important challenges in organizing and interpreting MCC findings. This important work suggests some methodological steps when considering MCC analyses:
Clearly specify the research and programmatic questions and their relevance to public health and clinical practice.
Clearly specify all assumptions and definitions used in identifying chronic conditions and their associated risk factors and outcomes.
Identify and use the most relevant data to address the questions at hand; this may require using multiple data systems.
Attempt to incorporate the patient’s views of illness and suffering into the interpretation of MCC data.
The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions.